INS and Hypoglycemia: In summary, the present meta-analysis indicates that pramlintide treatment as an adjunct to insulin therapy in T1DM patients has significantly improved glycemic control, reduced insulin dose and decreasing body weight, while showing nausea, vomiting, anorexia and hypoglycaemia in the initial titration phase.